Deep Learning-enhanced Personalized Monitoring of Aortic Stenosis - The DETECT-AS Prognostic Study
Launched by YALE UNIVERSITY · Dec 19, 2024
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The DETECT-AS Prognostic Study is a clinical trial designed to improve how we monitor and assess the risk for older adults with aortic stenosis, a condition where the heart's aortic valve narrows, making it harder for blood to flow. This study will test a new digital scoring system that helps doctors better understand a patient's risk based on their individual health data. The goal is to personalize care for patients with mild aortic stenosis or aortic sclerosis, which is a less severe form of the condition.
To participate in this study, individuals must be 65 years or older and have had an echocardiogram (a heart ultrasound) within the last 2-3 years showing either aortic sclerosis or mild aortic stenosis. Unfortunately, people with certain conditions, such as a history of heart valve replacement, implantable heart devices, or severe dementia, will not be eligible. Participants will be asked to attend a study visit at an echocardiogram lab within four years of their last echocardiogram, where they will help researchers gather important information about their heart health. This study is currently not recruiting participants but aims to enhance care for older adults with heart conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 65 years or older
- • 2. Prior transthoracic echocardiogram within the past 2-3 years showing aortic sclerosis without stenosis or mild AS
- Exclusion Criteria:
- • 1. Opted out of research studies
- • 2. Non-English speaking
- • 3. Any echocardiogram within 24 months of medical record review.
- • 4. Prior history of aortic valve replacement or repair, including transcatheter and surgical AVR with either a bioprosthetic or mechanical valve
- • 5. Presence of implantable cardiac devices, including permanent cardiac pacer, implantable cardioverter-defibrillator, or left ventricular assist device
- • 6. Prior heart transplant
- • 7. History of dementia
- • 8. Unable to attend study visit at echocardiogram lab within four years of most recent echocardiogram.
- • 9. Documented life expectancy of \<1 year or current participation in hospice services
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Houston, Texas, United States
Santa Clara, California, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
Rohan Khera, MD, MS
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported